Title

Oral delivery of xenon for cardiovascular protection

Authors

Xing Yin, Division of Cardiovascular Medicine, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, 77030, USA.
Melanie R. Moody, Division of Cardiovascular Medicine, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, 77030, USA.
Valeria Hebert, Department of Comparative Biomedical Science, School of Veterinary Medicine, Louisiana State University Health Science Center, Shreveport, Louisiana, 71103, USA.
Melvin E. Klegerman, Division of Cardiovascular Medicine, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, 77030, USA.
Yong-Jian Geng, Division of Cardiovascular Medicine, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, 77030, USA.
Tammy R. Dugas, Department of Comparative Biomedical Science, School of Veterinary Medicine, Louisiana State University Health Science Center, Shreveport, Louisiana, 71103, USA.
David D. McPherson, Division of Cardiovascular Medicine, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, 77030, USA.
Hyunggun Kim, Division of Cardiovascular Medicine, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, 77030, USA. hkim.bme@skku.edu.
Shao-Ling Huang, Division of Cardiovascular Medicine, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, 77030, USA. Shaoling.Huang@uth.tmc.edu.

Document Type

Article

Publication Date

10-1-2019

Abstract

Cardiac hypertrophy often causes impairment of cardiac function. Xenon (Xe), a naturally occurring noble gas, is known to provide neurological and myocardial protection without side effects. The conventional method of Xe delivery by inhalation is not feasible on a chronic basis. We have developed an orally deliverable, effective Xe formulation for long-term administration. We employed 2-hydroxypropyl)-β-cyclodextrin (HPCD), which was dissolved in water to increase the Xe concentration in solution. The beneficial effects of long-term oral administration of Xe-enriched solutions on cardiovascular function were evaluated in vivo. HPCD increased Xe solubility from 0.22 mM to 0.67 mM (3.8-fold). Aged ApoE knockout mice fed high-fat diet for 6 weeks developed hypertension, and myocardial hypertrophy with impaired cardiac function. Oral Xe prevented this ischemic damage, preserving normal blood pressure, while maintaining normal left ventricular mass and wall thickness. This novel formulation allows for gastrointestinal delivery and cardiovascular stabilization.

Publication Source (Journal or Book title)

Scientific reports

First Page

14035

This document is currently not available here.

COinS